– Fluorouracil Cream 0.5% approved by USFDA for actinic keratoses treatment.
– Manufactured in Texas, this cream is a generic equivalent of Carac.
– Collaboration aims to enhance patient access to cost-effective treatments.
Extrovis AG and Dr Reddy’s Laboratories have launched Fluorouracil Cream, 0.5 percent, an authorised generic of Carac, in the United States. The U.S. Food and Drug Administration (USFDA) approved this product, which is indicated for the topical treatment of multiple actinic or solar keratoses on the face and anterior scalp. The cream is manufactured in Texas at one of Extrovis’ facilities.
This launch represents a significant step in increasing patient access to effective treatments for skin conditions. Hans R. Kamma, Co-CEO and Chief Strategy Officer of Extrovis AG, emphasized the importance of this product in enhancing long-term value for the U.S. healthcare system. He stated that the partnership with Dr Reddy’s ensures that patients and healthcare providers have continued access to a high-quality and cost-effective product.
Dr Reddy’s Laboratories brings extensive expertise in commercialization and distribution within the U.S. market, which is crucial for the successful launch of this product. Raghavendra Rao PV, Chief Financial Officer of Extrovis AG, noted that this collaboration aligns with their mission to strengthen pharmaceutical supply chains and responsibly serve public health needs.
The introduction of Fluorouracil Cream, 0.5 percent, is expected to impact the market positively by providing a more affordable option for patients suffering from actinic keratoses. This condition affects millions of individuals in the U.S., making access to effective treatments essential for public health.
In summary, the launch of this authorised generic not only enhances treatment options but also supports the ongoing efforts to improve patient access to necessary medications in the U.S. healthcare landscape.